Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06625034 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer
A Phase 3 study of Prostate Carcinoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 108
- Enrollment target
- 1
- Study location
NCT06625034: Recruiting Phase 3 study of Prostate Carcinoma, sponsored by Mayo Clinic.
NCT06625034 is a Phase 3 study of Prostate Carcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 108 participants, below the 1,500-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06625034, a Phase 3 study of Prostate Carcinoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 108 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase III trial compares the effects of radiation therapy using RapidPlan, trademark, knowledge-based planning to human-driven planning in treating patients with prostate cancer. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Successful delivery of radiation requires planning to develop a treatment plan for how and where the radiation is to be delivered. RapidPlan is a knowledge-based treatment planning tool that automatically creates an optimal treatment plan based on identified targets and organs at risk for radiation exposure. Human-driven treatment planning by a dosimetrist, the current standard of care, requires significant resources and time and may vary within and among radiation centers. Giving radiation therapy with RapidPlan knowledge-based planning may have similar or less side effects compared to human-driven planning in treating patients with prostate cancer.
Primary Outcome
AEs will be defined using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Comparisons between treatment arms will be made using a non-inferiority test for the difference between two proportions with an alpha level of 5%. The proportion of patients experiencing grade 3 or higher GU or GI AEs over the number of patients eligible for toxicity will be estimated.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Positron Emission Tomography
- OTHER Questionnaire Administration
- RADIATION Photon Beam Radiation Therapy
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2025-02-02 |
| Est. Completion | 2033-05-28 |
| Phase | Phase 3 |
What NCT06625034 shows while recruiting
NCT06625034 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 1,500-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Prostate Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06625034 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT06625034 about?
NCT06625034 is a clinical study titled "Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer". This phase III trial compares the effects of radiation therapy using RapidPlan, trademark, knowledge-based planning to human-driven planning in treating patients with prostate cancer. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Su...
What is the current status of trial NCT06625034?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 108 participants. The study started on 2025-02-02. Estimated completion is 2033-05-28.
What conditions does trial NCT06625034 study?
This clinical trial studies the following conditions: Prostate Carcinoma.
What interventions are being tested in trial NCT06625034?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Positron Emission Tomography (PROCEDURE), Questionnaire Administration (OTHER), Photon Beam Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT06625034?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06625034 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06625034's enrollment target sits among peer trials
108 25th of 59 higher than 35 of 59 other Prostate Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
ACTIVE NOT RECRUITING · Phase 3
-
Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)
ACTIVE NOT RECRUITING · Phase 3
-
Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE
RECRUITING · NA
-
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
RECRUITING · Early Phase 1
-
Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)
RECRUITING
-
An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI